Pierre Marc Marie Joseph Deprez

This inventor holds 6 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Galapagos Nv, Les Laboratoires Servier, Les Laboratories Servier. Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre Marc Marie Joseph Deprez. Retrieved from https://idiyas.com/inventor/pierre-marc-marie-joseph-deprez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 10.6

ph-index = 2

Forward Citations = 7(Granted Patents)

Company Filing History:

Les Laboratoires Servier

patents

1 out of 53

Les Laboratories Servier

patents

where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11718588 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2023-08-08),

2. 10941117 - 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2021-03-09),

3. 10829478 - 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis (2020-11-10),

4. 10550100 - 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis (2020-02-04),

5. 10487060 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2019-11-26),

6. 9926281 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2018-03-27),

Title: Pierre Marc Marie Joseph Deprez: Innovator in Pharmaceutical Sciences

Introduction

Pierre Marc Marie Joseph Deprez is a notable inventor based in Romainville, France. With a remarkable portfolio of six patents, Deprez has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for the treatment of osteoarthritis.

Latest Patents

Among his latest innovations are the patents involving 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives. These compounds act as ADAMTS inhibitors, aimed at treating osteoarthritis. The invention encompasses compounds defined by a specific formula, wherein various substituents play a crucial role in their functionality. This involves methods for production, composition, and treatment methodologies related to inflammatory conditions and the preservation of cartilage homeostasis.

Career Highlights

Throughout his career, Pierre has worked with esteemed companies such as Galapagos NV and Les Laboratoires Servier. His work has advanced the field of pharmaceuticals, bringing innovative treatments to the forefront of medical science. His patents signify not only creativity but also a commitment to addressing pressing health issues.

Collaborations

Deprez has collaborated with notable colleagues, including Franck Laurent Brebion and Luke Jonathan Alvey. These partnerships have facilitated the exchange of ideas and expertise, enhancing the development of his pharmaceutical innovations.

Conclusion

In conclusion, Pierre Marc Marie Joseph Deprez stands out as a key inventor in pharmaceutical research. His innovative patents and collaborative spirit highlight his dedication to finding solutions for medical challenges, particularly in the realm of osteoarthritis treatment. His contributions significantly impact both the scientific community and patient care.

Profile summary based on public USPTO records.